About Celiac Disease
- Celiac Disease is a serious autoimmune disease.
- Ingestion of gluten in genetically predisposed people leads to damage in the small intestine.
- There are currently no approved therapeutic treatments for Celiac Disease.
What is the ACeD-it Study?
Phase 1b/2 Assessment of KAN-101 in Celiac Disease and Immune Tolerance
We are investigating a potential treatment for Celiac Disease in a phase 1b/2 clinical study.
Are you qualified for the ACeD-it trial study?
- ❯ 18-70 years old
- ❯ Diagnosed with biopsy-confirmed Celiac Disease
- ❯ Gluten free diet for more than 1 year
If you answered yes to all of these questions please use the link
below to find out if you can participate. Other criteria apply.
What is KAN-101?
KAN-101 is an investigational treatment for Celiac Disease. It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease. We deliver the antigen to the liver and immune system with our liver targeting glycosylation signature. KAN-101 was tested in humans in the Phase 1 ACeD study, which is now complete.
KAN-101 is in Phase 1b/2
About Clinical Research
We are ensuring that our clinical sites are adhering to national, state, local, and clinical site guidelines for COVID-19 .